Business Context and Reporting Period
This Form 8-K was filed by Immudyne, Inc. (not Lifemd, Inc.) on September 16, 2015. The report covers a corporate governance event occurring on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and contains no financial statements.
Material Changes
The material change reported is the appointment of Sven Rohmann, M.D., PhD, M.B.A. to the Company's board of directors on September 16, 2015.
Guidance, Outlook, and Risks
- Management Commentary: The Company confirmed there is no arrangement or understanding between Dr. Rohmann and any other person regarding his appointment.
- Related Transactions: No transactions or proposed transactions since January 1, 2014, involved Dr. Rohmann or his immediate family with a material interest.
- Family Relationships: No family relationships exist between Dr. Rohmann and other directors or executive officers.
- Risks and Contingencies: None disclosed in this filing.
Investor Verification Checklist
- Verify the correct registrant name is Immudyne, Inc., not Lifemd, Inc.
- Confirm Dr. Sven Rohmann's background and qualifications for the board role.
- Review subsequent filings for any financial impact or strategic shifts resulting from this board appointment.